Enrollment complete for Phase 3 trial testing Tyvaso in IPF patients
Enrollment is complete for a Phase 3 clinical trial testing Tyvaso (treprostinil) inhalation solution for idiopathic pulmonary fibrosis (IPF), United Therapeutics, the therapy’s developer, said. The TETON 2 study (NCT05255991) will evaluate the treatment’s safety and efficacy in 597 adults with IPF, 40 years and older,…